Abstract
At the blood-brain barrier, ATP-binding cassette (ABC) transporters, such as, P-glycoprotein (MDR1, ABCB1) and breast cancer related protein (BCRP, ABCG2) limit CNS uptake of foreign chemicals. Thus, they are neuroprotective, but they also distinguish poorly between neurotoxicants and therapeutic drugs. So they are major obstacles to CNS pharmacotherapy. The present review is focused on new findings in animal models in vitro and in vivo showing that basal transport activity of P-glycoprotein and Bcrp can be rapidly and transiently reduced through targeting of specific signaling pathways within the brain capillary endothelium. Three pathways have been identified: estrogen signaling to Bcrp, vascular endothelial growth factor signaling to P-glycoprotein and TNFα/PKC/ sphingolipid signaling to P-glycoprotein. Translation of these results to the clinic could provide improved pharmacotherapy for a number of CNS diseases, including, brain cancer, neuroAIDS and epilepsy.
Keywords: Neuroprotection, Drug delivery, ABC transporters, Blood-brain barrier, P-gp, efflux pumps.
Current Pharmaceutical Design
Title:Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Volume: 20 Issue: 10
Author(s): David S. Miller and Ronald E. Cannon
Affiliation:
Keywords: Neuroprotection, Drug delivery, ABC transporters, Blood-brain barrier, P-gp, efflux pumps.
Abstract: At the blood-brain barrier, ATP-binding cassette (ABC) transporters, such as, P-glycoprotein (MDR1, ABCB1) and breast cancer related protein (BCRP, ABCG2) limit CNS uptake of foreign chemicals. Thus, they are neuroprotective, but they also distinguish poorly between neurotoxicants and therapeutic drugs. So they are major obstacles to CNS pharmacotherapy. The present review is focused on new findings in animal models in vitro and in vivo showing that basal transport activity of P-glycoprotein and Bcrp can be rapidly and transiently reduced through targeting of specific signaling pathways within the brain capillary endothelium. Three pathways have been identified: estrogen signaling to Bcrp, vascular endothelial growth factor signaling to P-glycoprotein and TNFα/PKC/ sphingolipid signaling to P-glycoprotein. Translation of these results to the clinic could provide improved pharmacotherapy for a number of CNS diseases, including, brain cancer, neuroAIDS and epilepsy.
Export Options
About this article
Cite this article as:
Miller S. David and Cannon E. Ronald, Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990457
DOI https://dx.doi.org/10.2174/13816128113199990457 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evolution of the Human Ion Channel Set
Combinatorial Chemistry & High Throughput Screening Gender Medicine and Pharmacoeconomics: A Narrative Review of the International Literature of the Last 5 Years. A Revision of Evidences about the Relationship Between Gender and Economic Consumption in Health
Current Pharmaceutical Design Nutraceuticals in Psychiatric Practice
Recent Patents on CNS Drug Discovery (Discontinued) Neurotransmitters, Psychotropic Drugs and Microglia: Clinical Implications for Psychiatry
Current Medicinal Chemistry Functional Neuroimaging of Sleep Disorders
Current Pharmaceutical Design Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry The Orexin System: A Potential Player in the Pathophysiology of Absence Epilepsy
Current Neuropharmacology Recent Advances in Antiepileptic Herbal Medicine
Current Neuropharmacology Kv7 Channels as Targets for the Treatment of Pain
Current Pharmaceutical Design Human ABC Transporters at blood-CNS Interfaces as Determinants of CNS Drug Penetration
Current Pharmaceutical Design Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols
Letters in Drug Design & Discovery Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Nanotechnology in Neuroscience and its Perspective as Gene Carrier
Current Topics in Medicinal Chemistry Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets The NMDA Receptor NR2B Subunit: A Valid Therapeutic Target for Multiple CNS Pathologies
Current Medicinal Chemistry Targeting TRPs in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Expressed Emotion and Eating Disorders: An Updated Review
Current Psychiatry Reviews